Table 1.

Characteristics of patients in the B3 group and non-B3 group

CharacteristicsNon-B3 (n=111)B3 (n=90)
Age (yr), mean (SD)73.1 (12.4)65.6 (15.2)
Female, n (%)44 (40)40 (44)
Race, n (%)
 White non-Hispanic91 (82)27 (30)
 Black non-Hispanic11 (10)31 (34)
 Hispanic5 (5)13 (14)
 Asian2 (2)3 (3)
 Other2 (2)16 (18)
BMI (kg/m2), mean (SD)30.4 (7.8)32.2 (7.9)
Baseline creatinine (mg/dl), mean (SD)1.17 (0.47)1.20 (0.55)
eGFR <45 ml/min per 1.73 m2 at baseline, n (%)24 (22)22 (25)
Past diagnoses, n (%)
 COPD/asthma30 (27)13 (14)
 Diabetes mellitus49 (44)50 (56)
 Hypertension94 (85)70 (78)
 HF with reduced EF10 (9)5 (6)
 Malignancy17 (15)20 (22)
 Current or former tobacco use62 (56)34 (39)
Baseline medications, n (%)
 Statin76 (69)62 (69)
 ACEi/ARB48 (43)33 (37)
In-hospital medications, n (%)
 Hydroxychloroquine80 (72)40 (44)
 Azithromycin73 (66)51 (57)
 Remdesivira2 (2)11 (12)
 Sarilumaba0 (0)18 (20)
 Tocilizumab13 (12)10 (11)
Characteristics at day of eligibility
 Creatinine (mg/dl), mean (SD)2.02 (1.35)2.10 (1.32)
 KDIGO AKI stage, n (%)
  Stage 185 (77)68 (76)
  Stage 216 (14)13 (15)
  Stage 310 (9)8 (9)
 Hemoglobin (g/dl), mean (SD)11.4 (1.90)10.7 (2.19)
 WBC count (K/μl), mean (SD)8.62 (4.16)9.41 (5.20)
 Platelet count (K/μl), mean (SD)216 (108)255 (130)
 Bicarbonate (mEq/L), mean (SD)22.6 (4.93)23.5 (4.97)
 Potassium (mEq/L), mean (SD)4.22 (0.61)4.38 (0.56)
 On vasopressors, n (%)34 (31)52 (58)
 On mechanical ventilation, n (%)46 (41)56 (62)
 In ICU, n (%)53 (48)63 (70)
  • Non-B3, individuals not receiving niacinamide; B3, individuals receiving niacinamide; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HF, heart failure; EF, ejection fraction; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; KDIGO, Kidney Disease Improving Global Outcomes; WBC, white blood cell; ICU, intensive care unit.

  • a Patients were enrolled in a clinical trial of remdesivir or sarilumab, and it is unknown if they were receiving study drug or placebo.